Pharvaris N V

CUSIP N69605108COMPHVSQ1 2026

13D / 13G Filings

Schedule 13D/13G on record

Beneficial Filers

Distinct reporting persons

Largest Stake

14.1%

Max % of class reported

Institutional Holders

107

13F filers (latest quarter)

28 filings · latest Feb 17, 2026

#	Filed	Reporting Person	Form	% of Class	Shares	Filing
1	Feb 17, 2026	Bain Capital Life Sciences Fund, L.P.	13G/A	4.0%	1.64M	SEC
2	Nov 14, 2025	Bain Capital Life Sciences Fund, L.P.	13G/A	4.0%	1.87M	SEC
3	Aug 14, 2025	Venrock Healthcare Capital Partners III, L.P.	13G/A	3.8%	2.05M	SEC
4	Feb 14, 2024	Venrock Healthcare Capital Partners III, L.P.	13G/A	6.5%	3.40M	SEC
5	Feb 14, 2024	Viking Global Investors LP	13G/A	7.0%	3.66M	SEC
6	Feb 13, 2024	Foresite Capital Fund IV, L.P.	13G/A	7.8%	4.04M	SEC
7	Feb 13, 2024	General Atlantic, L.P.	13G/A	14.1%	7.53M	SEC
8	Feb 9, 2024	Fmr LLC	13G/A	10.0%	—	SEC
9	Feb 8, 2024	Lsp V Cooperatieve U.A.	13G/A	6.8%	3.56M	SEC
10	Jan 25, 2024	Venbio Global Strategic Fund III, L.P.	13D/A	6.8%	3.55M	SEC

See the full Schedule 13D/13G history for Pharvaris N V.

Largest reported positions · latest quarter

#	Fund	Shares	Value
1	General Atlantic, L.P.	8.03M	$226.88M
2	Fmr LLC	6.28M	$177.54M
3	Foresite Capital Management IV, LLC	4.78M	$134.99M
4	Venbio Partners LLC	4.64M	$131.06M
5	Viking Global Investors LP	3.65M	$103.21M
6	Eqt Fund Management S.A R.L.	3.42M	$96.75M
7	Deerfield Management Company, L.P.	3.13M	$88.31M
8	Bain Capital Life Sciences Investors, LLC	2.68M	$75.58M
9	Wellington Management Group LLP	2.12M	$59.86M
10	Commodore Capital LP	1.92M	$54.21M